Literature DB >> 26884598

ONC201: Stressing tumors to death.

Yoshimi Endo Greer1, Stanley Lipkowitz2.   

Abstract

The small molecule ONC201 was identified in a screen for compounds that would induce expression of the gene encoding tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) in tumors and thus cause an autocrine- or paracrine-induced death in tumor cells. Two Research Articles in this issue of Science Signaling by Ishizawa et al. and Kline et al. describe how ONC201 can also trigger cytotoxicity by inducing a stress response. The mechanisms of the stress response induced differ between hematological malignancies and solid tumors, highlighting the complexity of ONC201-induced toxicity and raising intriguing issues of tissue-specific pathways activated by the drug.
Copyright © 2016, American Association for the Advancement of Science.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26884598      PMCID: PMC7422919          DOI: 10.1126/scisignal.aad7955

Source DB:  PubMed          Journal:  Sci Signal        ISSN: 1945-0877            Impact factor:   8.192


  16 in total

1.  ONC201 induces cell death in pediatric non-Hodgkin's lymphoma cells.

Authors:  Mala K Talekar; Joshua E Allen; David T Dicker; Wafik S El-Deiry
Journal:  Cell Cycle       Date:  2015-06-01       Impact factor: 4.534

Review 2.  Regulated cell death: signaling and mechanisms.

Authors:  Avi Ashkenazi; Guy Salvesen
Journal:  Annu Rev Cell Dev Biol       Date:  2014-08-13       Impact factor: 13.827

Review 3.  Cell intrinsic and extrinsic activators of the unfolded protein response in cancer: Mechanisms and targets for therapy.

Authors:  Feven Tameire; Ioannis I Verginadis; Constantinos Koumenis
Journal:  Semin Cancer Biol       Date:  2015-04-25       Impact factor: 15.707

4.  An integrated stress response regulates amino acid metabolism and resistance to oxidative stress.

Authors:  Heather P Harding; Yuhong Zhang; Huiquing Zeng; Isabel Novoa; Phoebe D Lu; Marcella Calfon; Navid Sadri; Chi Yun; Brian Popko; Richard Paules; David F Stojdl; John C Bell; Thore Hettmann; Jeffrey M Leiden; David Ron
Journal:  Mol Cell       Date:  2003-03       Impact factor: 17.970

Review 5.  Roles of CHOP/GADD153 in endoplasmic reticulum stress.

Authors:  S Oyadomari; M Mori
Journal:  Cell Death Differ       Date:  2004-04       Impact factor: 15.828

Review 6.  The TRAIL apoptotic pathway in cancer onset, progression and therapy.

Authors:  Ricky W Johnstone; Ailsa J Frew; Mark J Smyth
Journal:  Nat Rev Cancer       Date:  2008-10       Impact factor: 60.716

Review 7.  Cell death and endoplasmic reticulum stress: disease relevance and therapeutic opportunities.

Authors:  Inki Kim; Wenjie Xu; John C Reed
Journal:  Nat Rev Drug Discov       Date:  2008-12       Impact factor: 84.694

Review 8.  The TRAIL to targeted therapy of breast cancer.

Authors:  Monzur Rahman; Janet G Pumphrey; Stanley Lipkowitz
Journal:  Adv Cancer Res       Date:  2009       Impact factor: 6.242

9.  Dual inactivation of Akt and ERK by TIC10 signals Foxo3a nuclear translocation, TRAIL gene induction, and potent antitumor effects.

Authors:  Joshua E Allen; Gabriel Krigsfeld; Patrick A Mayes; Luv Patel; David T Dicker; Akshal S Patel; Nathan G Dolloff; Evangelos Messaris; Kimberly A Scata; Wenge Wang; Jun-Ying Zhou; Gen Sheng Wu; Wafik S El-Deiry
Journal:  Sci Transl Med       Date:  2013-02-06       Impact factor: 17.956

10.  Identification of TRAIL-inducing compounds highlights small molecule ONC201/TIC10 as a unique anti-cancer agent that activates the TRAIL pathway.

Authors:  Joshua E Allen; Gabriel Krigsfeld; Luv Patel; Patrick A Mayes; David T Dicker; Gen Sheng Wu; Wafik S El-Deiry
Journal:  Mol Cancer       Date:  2015-05-01       Impact factor: 27.401

View more
  12 in total

1.  Small molecule ONC201 inhibits HIV-1 replication in macrophages via FOXO3a and TRAIL.

Authors:  Runze Zhao; Yuju Li; Santhi Gorantla; Larisa Y Poluektova; Hai Lin; Fengtong Gao; Hongyun Wang; Jeffrey Zhao; Jialin C Zheng; Yunlong Huang
Journal:  Antiviral Res       Date:  2019-05-31       Impact factor: 5.970

Review 2.  Promising new treatments for pancreatic cancer in the era of targeted and immune therapies.

Authors:  Ahmed Elaileh; Ashish Saharia; Lucy Potter; Flavio Baio; Afnan Ghafel; Maen Abdelrahim; Kirk Heyne
Journal:  Am J Cancer Res       Date:  2019-09-01       Impact factor: 6.166

3.  ONC201 Targets AR and AR-V7 Signaling, Reduces PSA, and Synergizes with Everolimus in Prostate Cancer.

Authors:  Avital Lev; Amriti R Lulla; Brian C Ross; Marie D Ralff; Petr B Makhov; David T Dicker; Wafik S El-Deiry
Journal:  Mol Cancer Res       Date:  2018-03-27       Impact factor: 5.852

4.  ONC201 demonstrates anti-tumorigenic and anti-metastatic activity in uterine serous carcinoma in vitro.

Authors:  Ziwei Fang; Jiandong Wang; Leslie H Clark; Wenchuan Sun; Yajie Yin; Weimin Kong; Stuart R Pierce; Lindsay West; Stephanie A Sullivan; Arthur-Quan Tran; Varun V Prabhu; Chunxiao Zhou; Victoria Bae-Jump
Journal:  Am J Cancer Res       Date:  2018-08-01       Impact factor: 6.166

5.  Small Molecular TRAIL Inducer ONC201 Induces Death in Lung Cancer Cells: A Preclinical Study.

Authors:  Yuan Feng; Jihong Zhou; Zhanhua Li; Ying Jiang; Ying Zhou
Journal:  PLoS One       Date:  2016-09-14       Impact factor: 3.240

6.  Anti-pancreatic cancer activity of ONC212 involves the unfolded protein response (UPR) and is reduced by IGF1-R and GRP78/BIP.

Authors:  Avital Lev; Amriti R Lulla; Jessica Wagner; Marie D Ralff; Joshua B Kiehl; Yan Zhou; Cyril H Benes; Varun V Prabhu; Wolfgang Oster; Igor Astsaturov; David T Dicker; Wafik S El-Deiry
Journal:  Oncotarget       Date:  2017-09-12

7.  ONC201 activates ER stress to inhibit the growth of triple-negative breast cancer cells.

Authors:  Xun Yuan; Dhonghyo Kho; Jing Xu; Ambikai Gajan; Kongming Wu; Gen Sheng Wu
Journal:  Oncotarget       Date:  2017-03-28

8.  Identification of DNA-PKcs as a primary resistance factor of TIC10 in hepatocellular carcinoma cells.

Authors:  Long Cheng; Yuan-Yuan Liu; Pei-Hua Lu; Yi Peng; Qiang Yuan; Xin-Shi Gu; Yong Jin; Min-Bin Chen; Xu-Ming Bai
Journal:  Oncotarget       Date:  2017-04-25

Review 9.  Discovery and clinical introduction of first-in-class imipridone ONC201.

Authors:  Joshua E Allen; C Leah B Kline; Varun V Prabhu; Jessica Wagner; Jo Ishizawa; Neel Madhukar; Avital Lev; Marie Baumeister; Lanlan Zhou; Amriti Lulla; Martin Stogniew; Lee Schalop; Cyril Benes; Howard L Kaufman; Richard S Pottorf; B Rao Nallaganchu; Gary L Olson; Fahd Al-Mulla; Madeleine Duvic; Gen Sheng Wu; David T Dicker; Mala K Talekar; Bora Lim; Olivier Elemento; Wolfgang Oster; Joseph Bertino; Keith Flaherty; Michael L Wang; Gautam Borthakur; Michael Andreeff; Mark Stein; Wafik S El-Deiry
Journal:  Oncotarget       Date:  2016-11-08

10.  ONC201 kills breast cancer cells in vitro by targeting mitochondria.

Authors:  Yoshimi Endo Greer; Natalie Porat-Shliom; Kunio Nagashima; Christina Stuelten; Dan Crooks; Vishal N Koparde; Samuel F Gilbert; Celia Islam; Ashley Ubaldini; Yun Ji; Luca Gattinoni; Ferri Soheilian; Xiantao Wang; Markus Hafner; Jyoti Shetty; Bao Tran; Parthav Jailwala; Maggie Cam; Martin Lang; Donna Voeller; William C Reinhold; Vinodh Rajapakse; Yves Pommier; Roberto Weigert; W Marston Linehan; Stanley Lipkowitz
Journal:  Oncotarget       Date:  2018-04-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.